Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Sajid Khan, Yonghan He, Xuan Zhang, et al.
Oncogene (2020) Vol. 39, Iss. 26, pp. 4909-4924
Open Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1681
An expanded lexicon for the ubiquitin code
Ivan Đikić, Brenda A. Schulman
Nature Reviews Molecular Cell Biology (2022) Vol. 24, Iss. 4, pp. 273-287
Open Access | Times Cited: 201
E3 ubiquitin ligases: styles, structures and functions
Quan Yang, Jinyao Zhao, Dan Chen, et al.
Molecular Biomedicine (2021) Vol. 2, Iss. 1
Open Access | Times Cited: 195
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe, Craig M. Crews
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 934-951
Open Access | Times Cited: 171
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Jianwei Qu, Haimeng Yan, Yifan Hou, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 127
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 125
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Dongwen Lv, Pratik Pal, Xingui Liu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 99
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 84
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 66
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 53
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand Kornepati, Cody M. Rogers, Patrick Sung, et al.
Nature (2023) Vol. 619, Iss. 7970, pp. 475-486
Closed Access | Times Cited: 41
Discovery of Nanomolar DCAF1 Small Molecule Ligands
Alice Shi Ming Li, Serah Kimani, Brian J. Wilson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 5041-5060
Open Access | Times Cited: 36
PROTACs to address the challenges facing small molecule inhibitors
Pedro Martín-Acosta, Xiangshu Xiao
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112993-112993
Open Access | Times Cited: 97
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Yufeng Xiao, Jia Wang, Lisa Zhao, et al.
Chemical Communications (2020) Vol. 56, Iss. 68, pp. 9866-9869
Open Access | Times Cited: 90
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 87
Druggable genome and precision medicine in cancer: current challenges
Camille Dupont, Kristina Riegel, Malvika Pompaiah, et al.
FEBS Journal (2021) Vol. 288, Iss. 21, pp. 6142-6158
Open Access | Times Cited: 69
Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
Lin Zhang, Ling Li, Xia Wang, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 66-79
Open Access | Times Cited: 62
The rise of covalent proteolysis targeting chimeras
Ronen Gabizon, Nir London
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 24-33
Closed Access | Times Cited: 60
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 60
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
Gabriel LaPlante, Wei Zhang
Cancers (2021) Vol. 13, Iss. 12, pp. 3079-3079
Open Access | Times Cited: 55
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 54
Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2
Wenguang Yang, Wenjia Liu, Xiang Li, et al.
Journal of Advanced Research (2022) Vol. 45, pp. 59-71
Open Access | Times Cited: 51
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Gustavo P. Amarante-Mendes, Aamir Rana, Tarcila Santos Datoguia, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 215-215
Open Access | Times Cited: 50
PROTAC therapy as a new targeted therapy for lung cancer
Jennifer W. Li, Guangrong Zheng, Frederic J. Kaye, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 647-656
Open Access | Times Cited: 42
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114142-114142
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top